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↑What is “already known” in this topic: 
PCI strategy was more cost-effective in reducing mortality rate, 
and in the context of improving QoL, medical therapy strategy 
was cost-effective.   
 
→What this article adds: 
This study may have significant policy and clinical 
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Abstract 
Background: Ischemic heart disease is categorized into two acute and chronic groups, and its treatments include revascularization and 
medical therapy. The aim of this study is to evaluate the economic burden of medical therapy compared to percutaneous coronary 
intervention in ischemic heart disease. 
Methods: This study has been done in two steps. The first was a systematic review and meta-analysis to measure the effectiveness of 
two interventions and the second step was a cost-effectiveness analysis from the perspective of society. The data analysis included a 
meta-analysis and the Markov cohort simulation. RewMan v5 and tree age software were utilized. Uncertainties related to the model 
parameters were evaluated using one-way and two-way sensitivity analyses. 
Results: Regarding the effectiveness of interventions, the odd ratio of the quality of life in the medical therapy group (CI: 0.76-1.10) 
was 0.91 times the PCI group (p=0.34). This rate for mortality in medical therapy (CI: 0.52-9.68) was 2.23 times more than the PCI 
group; this result was not significant (p=0.02). In the cost-effectiveness analysis, the cost-effectiveness threshold was $ 16,482; ICER 
in increasing the QoL and reduction in the mortality rate was $ 25320.11 and $ 562.6691, respectively. Regarding the sensitivity 
analysis, the model was not sensitive in changing parameters in a specific domain. 
Conclusion: According to this study, PCI is more cost-effective than medical therapy in the reduction of mortality rate and in the field 
of increasing quality of life. MT strategy is more cost-effective than the PCI. This study considers controversies regarding the most 
appropriate treatment for patients with ischemic heart disease that is helpful for health policymakers, cardiologists and health 
managers. 
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Ischemic heart diseases are the most prevalent causes of 
diseases admitted in hospitals and are the second cause of 
mortality in Iran. Treatment cost for most of these pre-
ventable causes of readmission is remarkably high (1). 
Ischemic heart disease, a group of heart failure, are cate-
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disease is a condition that results from a decrease in myo-
cardial perfusion. These diseases are often caused by cor-
onary artery occlusion, such as atherosclerosis. Risk fac-
tors that develop ischemic heart disease are unhealthy 
blood cholesterol levels, hypertension, smoking, diabetes 
mellitus, obesity, lack of physical activity, age and so on. 
And complications of this disease are Chest pain, left 
shoulder pain, shortness of breath and weakness (2, 3). 
Cardiovascular disease is one of the top 10 causes of 
death in the world, accounting for 25 to 45 percent of the 
world's mortality as the leading cause of death and the 
fifth leading cause of disability. 17/3 million people 
worldwide died in 2008 due to cardiovascular disease, 
which accounts for about 30% of all deaths. 80 percent of 
these deaths occur in poor and middle-income countries. 
The same death rate is expected to reach 23.6 million by 
2030 (4-6). Economic evaluation of cardiovascular inter-
ventions plays an important role in decisions about reim-
bursement, pricing of health care, providing clinical guid-
ance on the use of existing clinical technologies, strategic 
acquisition of these interventions, providing targeted 
health care, and generating scientific evidence to make 
policy decisions and ultimately allocate optimal financial 
resources to the health of the cardiovascular disease area 
(7, 8).  
There are several methods for treating ischemic heart 
disease, which include: Medical therapy, such as the use 
ACE inhibitors, β-blockers, Angiotensin receptor block-
ers, Mineral corticoid receptor antagonists, Angiotensin 
receptor neprilysin inhibitor, diuretics, antiplatelet, and 
lipid regulating drugs. Coronary angioplasty or PCI meth-
od that is used to open the closed arteries of the heart. In 
angioplasty, a small balloon is temporarily inserted into 
the closed area of the artery to help widen it (9-11). 
According to studies, the global cost of cardiovascular 
diseases in 2010 was estimated at $ 863 billion (average 
per capita cost of $ 125), which will grow by 22% to $ 
1044 billion by 2030 and it is predicted that Cardiovascu-
lar disease is a major contributor to the disability of active 
individuals that can severely affect the productivity of 
active labor force in society and reduce GDP and national 
income (12). 
Percutaneous coronary intervention (PCI) and medical 
therapy are widely performed as treatment for ischemic 
heart disease. The cost of this interventions are much so it 
is essential to consider the economic evaluation of PCI 
and medical therapy for ischemic heart disease (7). 
Kodera et al concluded that in ST-elevation myocardial 
infarction patients, PCI was cost-effective compared to 
medical therapy (7); and Harindra et al concluded that In 
patients with stable coronary artery disease, an initial 
bare-metal stent (BMS) strategy is cost-effective (13). It is 
known that the costs of medical interventions are rising 
worldwide, regardless of the development of modern med-
ical technology. Economic evaluations have been emerged 
as an important tool to allocate scarce resources efficiently 
and rationally. Methods of economic evaluations are ap-
plied to assess health care programs in many arenas con-
taining treatments of ischemic heart disease which impose 
a high burden on economics worldwide (14, 15). 
In this study, the costs of interventions under review are 
identified from the society perspective, including thera-
peutic and non-therapeutic direct costs and indirect costs. 
Ouraim was to evaluate the incremental cost-effectiveness 
rate (ICER) of PCI and medical therapy for patients with 




This research has been done in two steps. The first is 
systematic review and meta-analysis to measure the effec-
tiveness of PCI and medical therapy (mortality rate and 
quality of life), and the other is a cost-effectiveness analy-
sis. The systematic review stage included observational 
and interventional studies in English and Persian language 
from 2000 to 2018 and examined the effectiveness of in-
terventions in patients with ischemic heart disease. Also 
the quality of all studies is evaluated by the Jadad score 
(16); meta-analysis was done using RewMan v5 software. 
We analyzed the results based on the OR. P<0.05 was 
statistically significant(17). To test heterogeneity, the I2 
test was used and because of the high heterogeneity the 
random effects method is used.  
In the second step, a Markov model has been used to 
model outcomes for patients with ischemic heart disease. 
The cycle length was 20 years because the average age 
difference of patients to life expectancy in Iran is 20 years. 
Outcomes were a reduction in mortality and an increase in 
quality of life. The analysis was done from the perspective 
of society. All outcomes were discounted at 3% per year. 
Inclusion criteria were patients with ischemic heart dis-
ease with ejection fraction less than 40%. Patients were 
randomly assigned to a treatment group. Ethics Commit-
tee of the Iran University of Medical Sciences approved 
the study. 
The two strategies evaluated were medical therapy and 
PCI. The simplified schematic of the Markov model struc-
ture is shown in Figure 1.Clinical experts̓ opinions and 
reviewing the literature (13, 18, 19) were used in order to 
determine the transmission probability. We arbitrarily 
defined an intervention “cost-effective” if it was less than 
three times the GDP per capita and “not cost-effective” if 
it was higher than three times the GDP per capita. The 
cost-effectiveness threshold was set according to the offi-
cial dollar rate in Iran in 2018. One-way and two-way 
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(The costs of two interventions, mortality rate, and quality 
of life and transition probabilities) including the discount 
rate from 0% to 3%. 
 
Results  
In this study, 520 patients with ischemic heart disease 
were studied that 300 of them were in the PCI group and, 
220 of them were in the medical therapy group. Baseline 
characteristics of the patients are shown in Table 1. 
According to Table 1, average age was 53 and 52 years 
in PCI and MT interventions, respectively. The majority 
of patients were male (80±2). On average, 61% of patients 
had hypertension, and prevalence of diabetes mellitus in 
patients was approximately 30%, 1% of patients had 
dyslipidemia, In both groups, Killip class ≥2 and CCS 
class ≥2 were estimated at about 25% and 60% of patients 
had Single-vessel disease. 
In the systematic and meta-analysis step, study selection 
procedures are followed according to the PRISMA flow 
diagram. Finally six full text articles were included in the 
final analysis (20-25). All the final studies were published 
between 2000 and 2018. And the random-effects model 
was selected. In this step experimental and control group 
were include PCI and MT respectively. The results of first 
step are summarized in Figure 2.In the context of this in-
dicator mortality rate in medical group in CI: 0.52-9.68 
was 2.23 times the PCI group but this result was not sig-
nificant in p=0.02. 
Also, the results of the study in context to quality of life 
are shown in Figure 3. The odd ratio of quality of life in 
medical therapy group in CI: 0.76-1.10 is 0.91 but this 
result was not significant in p=0.34. 
 
Cost-effectiveness analysis 
This study was conducted on 520 patients with ischemic 
heart disease in Iran's referral hospitals in 2018. The cost-
effectiveness threshold was $ 16,482 and the results of the 
incremental cost-effectiveness graph were analyzed based 
on this threshold. The cost-effectiveness plan presented in 
Figures 4 and 5 and the results of the cost-effectiveness of 
two interventions in reducing patient mortality and in-
creasing quality of life in these patients are summarized in 
Table 2. 
As shown in Table 2, ICER is equal to 562.66 per a unit 
reduction in mortality rate and Willingness to pay is $ 
16,482, as a result, both interventions are cost-effective 
 
Table 1.Baseline characteristic 
Baseline characteristic PCI Medical Therapy 
Average age (years) 53 52 
Male (%) 80 78 
Hypertension (%) 62 60 
Diabetes mellitus (%) 30 28 
Dyslipidemia (%) 48 48 
Killip class1 ≥2 (%) 25 26 
CCS1 class ≥2 (%) 24 25 
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but because the average cost-effectiveness of PCI is less 
than medical therapy, PCI strategy is more cost-effective 
than medical therapy. Also according to this table, ICER 
is equal to 25320.11 per a unit of increase in quality of life 
Therefore; none of the interventions are cost-effective but 
since the average cost-effectiveness of medical therapy is 
less than PCI as a result MT strategy is more cost-
effective than PCI. 
 
Sensitivity analysis 
In this study, first all variables related to the cost and ef-
fectiveness of two interventions were selected for sensitiv-
ity analysis using the Tornado chart. Then, the variable 
with the most effect on the study result was selected and, 
the one-way sensitivity analysis was performed on it. In 
mortality reduction dimension, the mortality reduction 
parameter in PCI strategy was selected for analysis and by 
doing the sensitivity analysis did not change the results of 
cost-effectiveness. Also in this dimension, the two-way 
sensitivity analysis did not change the results of cost-
effectiveness (Fig. 6). According to the increasing trend in 
the quality of life dimension, one-way and two-way sensi-
tivity analysis did not change the results of the cost-
effectiveness analysis (Fig. 7). Therefore, the model was 
not sensitive to changing parameters in a specific domain. 
 
Discussion  
In this cost-effectiveness analysis of medical therapy 
compared to PCI for ischemic heart disease, we construct-
ed a Markov model of treatments for patients in order to 
compare costs and effectiveness of two interventions 
based on systematic review and disease costs question-
naire depend on society perspective. We performed a life-
time analysis covering patient life expectancy using a long 
term period of 20 years. According to the results of pre-
sent study, PCI strategy is more cost-effective than medi-
cal therapy in reduction of mortality rate. Gada et al (26) 
concluded that PCI is cost-effective in a patient with heart 
severe symptoms and Quality-of-life criteria, and PCI 
should be used more frequently than medical therapy. 
Wong et al (27)concluded that PCIis more cost-effective 
 
 
Fig. 4. Cost-Effectiveness plan for reduction in mortality rate 
 
 
Fig. 5. Cost-Effectiveness plan for Quality of Life 
 
 
Fig. 6. Two-way sensitivity analysis for reduction in mortality 




Fig. 7. Two-way sensitivity analysis for Quality of life index 
 
Table 2.Cost Effectiveness Analysis 
Indicator Intervention Cost $ Effectiveness Average CE ICER EV 
Reduction in mortality MT 15262.11 26.39372 578.2476 0 578.2476 PCI 24094.16 42.09043 572.438 562.6691 572.438 
QoL MT 15262.11 8.487849 1798.112 0 1798.112 PCI 24094.16 8.836665 2726.612 25320.11 2726.612 
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than medical therapy in patients with severe angina. 
Claude J et al.(28)concluded that PCI improved clinical 
effectiveness at only marginally higher costs and was 
cost-effective; so costs should not be argued against inva-
sive management of elderly patients with chronic angina. 
Kinlay S (29)  concluded that from society's perspective, 
Percutaneous Transluminal Coronary Angioplasty  
(PTCA) may be more cost-effective than a medical thera-
py. So when percutaneous coronary intervention is used, 
the hospital's financial interests are best retained the use of 
percutaneous coronary intervention for people with pri-
vate insurance can be effective. And cost-shifting may 
have a major impact on the provision of PCI and the costs 
of providing medical services need to be weighed against 
the cost of not providing them. The results of all these 
studies are consistent with the results of the present study. 
This study also showed that, considering the increasing 
quality of life, MT strategy is more cost-effective than the 
PCI. Griffin et al.(30) in their study on the comparison of 
the effectiveness of CABG and PCI compared with medi-
cal therapy in patients with angina pectoris concluded that 
medical therapy was a cost-effective strategy in patients 
under their study. Vieira et al. (31) Concluded that in the 
long-term economic analysis, medical therapy was more 
cost-effective than Coronary Artery Bypass Grafting 
(CABG), and CABG was more cost-effective than PCI for 
patients with coronary artery disease. The strategy of PCI 
versus medical therapy was evaluated in the COURAGE 
trial, which found that PCI reduced angina symptoms and 
improved the quality of life at 3 years, but did not reduce 
the rate of death or MI. Besides that, PCI was not cost-
effective compared with medical therapy (32). Hlatky et 
al.(33)found that medical therapy in patients with heart 
failure was more cost-effective compared with PCI Strate-
gy. Ruffo showed that medical therapy dominates PTCA, 
allowing a greater number of patients to remain free of 
cardiovascular events at a lower cost (34). The results of 




Cost-effectiveness of PCI in ischemic heart disease 
must be considered. If PCI does not reduce cardiovascular 
death or MI when added to medical therapy, it is difficult 
to justify the cost of PCI for asymptomatic patients. Fur-
thermore, if PCI improves QoL, but does not reduce 
death, patients and payers need to know how much the 
cost of a period of freedom from angina is.  
The main strength of this economic analysis is that it is 
based on systematic review and meta-analysis in the field 
of effectiveness data and that the cost of treating patients 
was calculated and analyzed from the society perspective 
and its main limitations were the failure to consider coro-
nary artery bypass surgery intervention and the other limi-
tation is the model-based design. In model-based studies, 
when model assumptions vary, results vary. So we set 
reasonable models in the present study based on previous 
studies and clinical experts̓ opinions. 
This cost-effectiveness analysis of medical therapy 
compared to PCI found that PCI strategy was more cost-
effective in reducing mortality rate and in the context of 
improving QoL, medical therapy strategy was cost-
effective and the high PCI consumables cost highlighted 
the importance of cost-effective purchasing mechanism. 
The present study has the following clinical implication: 
PCI for ischemic heart disease should be performed more 
often in Iran, based on its cost-effectiveness in the reduc-
tion of mortality rate. This study may have significant 
policy and clinical implications for health policymakers, 
cardiologists and health managers. 
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